PFG Advisors Has $4.10 Million Stock Position in Stryker Co. (NYSE:SYK)

PFG Advisors cut its stake in Stryker Co. (NYSE:SYK) by 1.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,383 shares of the medical technology company’s stock after selling 131 shares during the period. PFG Advisors’ holdings in Stryker were worth $4,098,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of SYK. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker during the fourth quarter worth $25,000. Dunhill Financial LLC grew its holdings in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the 4th quarter worth about $30,000. BankPlus Trust Department bought a new position in Stryker during the 4th quarter valued at about $33,000. Finally, Darwin Wealth Management LLC acquired a new position in Stryker in the third quarter valued at about $36,000. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $365.35 on Wednesday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $139.41 billion, a PE ratio of 47.08, a PEG ratio of 2.93 and a beta of 0.95. The stock’s fifty day simple moving average is $382.70 and its 200 day simple moving average is $373.40.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 EPS. On average, research analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on SYK shares. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Citigroup restated a “buy” rating and set a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $421.90.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.